Pre-Open Movers 09/23: (MNOV) (ATHX) (NKE) Higher; (ACIU) (WVE) (SFIX) Lower (more...)

September 23, 2020 9:30 AM EDT
Get Alerts ACIU Hot Sheet
Price: $6.11 +1.16%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Pre-Open Stock Movers

AC Immune SA (NASDAQ: ACIU) 42.8% LOWER; announced that Genentech, a member of the Roche Group, has informed the Company of top line results from a Phase 2 trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimers disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo. Two secondary endpoints, Alzheimers Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimers Disease Cooperative Study Group Activities of Daily Living Inventory (ADCS-ADL) were also not met.

Wave Life Sciences Ltd. (Nasdaq: WVE) 31% LOWER; commenced an underwritten public offering of its ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering on the same terms and conditions. All of the shares in the offering will be sold by Wave Life Sciences.

MediciNova, Inc., (NASDAQ: MNOV) 20.8% HIGHER; announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.

Stitch Fix (NASDAQ: SFIX) 16.5% LOWER; reported Q4 EPS of ($0.44), $0.28 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $443.4 million versus the consensus estimate of $414.31 million.

Aurora Cannabis (NYSE: ACB) 16% LOWER; reported Q4 revenue of Cdn$72.1 million, a 5% decrease from the prior quarter.

Athersys, Inc., (Nasdaq: ATHX) 11.8% HIGHER; announced today that MultiStem® cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the acute respiratory distress syndrome (ARDS) program. The RMAT designation enables sponsors to work closely with the FDA and receive their guidance on expediting development of their products, including providing advice on generating the evidence needed to support approval in an efficient manner. RMAT designation invites the Company to schedule a Type B meeting with the FDA to discuss multidisciplinary strategic development plans, including expediting manufacturing development for commercialization to support priority review and/or accelerated approval.

Nike (NYSE: NKE) 11.7% HIGHER; reported Q1 EPS of $0.95, $0.49 better than the analyst estimate of $0.46. Revenue for the quarter came in at $10.6 billion versus the consensus estimate of $9.12 billion. Inventory rose 15 percent versus prior year but decreased 9 percent versus prior quarter.

Zogenix, Inc. (Nasdaq: ZGNX) 8.4% LOWER; announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act). Zogenix also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $30,000,000 principal amount of notes.

Livent Corporation (NYSE: LTHM) 8% LOWER; worries in the lithium market after Tesla's battery day

Steelcase (NYSE: SCS) 7.2% LOWER; reported Q2 EPS of $0.55, $0.18 better than the analyst estimate of $0.37. Revenue for the quarter came in at $818.8 million versus the consensus estimate of $782.6 million. Steelcase sees Q3 2021 EPS of $0.12-$0.18, versus the consensus of $0.18. Steelcase sees Q3 2021 revenue of $690-725 million, versus the consensus of $703.9 million.

Albemarle (NYSE: ALB) 7% LOWER; worries in the lithium market after Tesla's battery day

Sociedad Química y Minera de Chile S.A. (NYSE: SQM) 5.2% LOWER; worries in the lithium market after Tesla's battery day

JinkoSolar (NYSE: JKS) 4.2% HIGHER; reported Q2 EPS of $1.20, $0.59 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.14 billion.

Tesla (NASDAQ: TSLA) 4% HIGHER; sees gains amid battery day.

Neoleukin Therapeutics (NASDAQ: NLTX) 3.5% HIGHER; Baird initiates coverage on with an Outperform rating and a price target of $25.00.

Foot Locker (NYSE: FL) 2.9% HIGHER; gains on Nike's blow-out quarter.

Western Digital Corp. (Nasdaq: WDC) 2.6% HIGHER; announced a significant step in the ongoing implementation of its diversified storage portfolio strategy by forming separate product business units for its Flash and HDD technology assets. The Flash business and the HDD business will each be led by a general manager and will align the company’s diversified portfolio to an acceleration strategy designed for growth, profitability and development agility. By delivering both Flash and HDD market-leading innovation through highly focused product development organizations, Western Digital’s strategy positions the company to leverage its strong go-to-market and operational synergies and uniquely address broad customer storage needs from edge devices to cloud infrastructure.

lululemon athletica (NASDAQ: LULU) 2.4% HIGHER; to restart its previously authorized stock repurchase program

Dick's (NYSE: DKS) 1.6% HIGHER; gains on Nike's blow-out quarter.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Robert W Baird, Tesla, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA